Groupe d'Etude en Oncologie du Quebec

Title	A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors
Protocole ID	CA231-0000
ClinicalTrials.gov ID	NCT06476808
Cancer Type(s)	Ovary Uterine Sarcoma
Phase	Phase I
Stage
Study Type	Clinical
Drug	BMS-986463
Institution	CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
City
Principal Investigator	Dr. Susie Lau
Coordinator	Alessandra Figueiredo De Vasconcelos 514-340-8222 poste 26823
Status	Recruiting
Activation Date
Eligibility Criteria	Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained. Participants must have an unresectable/metastatic carcinoma.
Exclusion Criteria	Participants must not have Leptomeningeal metastases. Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment. Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment. Other protocol-defined Inclusion/Exclusion criteria apply.

Groupe d'étude en oncologie du Québec